# Engimmune Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/engimmune-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: http://www.engimmune.com
- Total disclosed funding: $16M
- Latest round: Seed (May 3, 2022)
- Investors on record: 2

## About

In 2021, the company was co-founded by Dr. Rodrigo Vazquez-Lombardii, who serves as the company CSO, Prof. Sai Reddy, who serves as Chairman of the Scientific Advisory Board (SAB), and Dr. Søren Mouritsen, who serves as the CEO of the company. In 2022, the company raised USD 16 million co-led by Pureos Bioventures and Novo Holdings. Along with this financing, the board appointed two investors Dr. Dominik Escher (Pureos) and Dr. Jørgen Sorberg Petersen (Novo) as directors in the company.

The company operates as a medical research company, developing medical methodologies to address the multiple challenges affecting the TCR-based therapeutic discovery and development process, offering innovative high-throughput solutions to TCR engineering and safety screening. The company's platform technology combines three methods in the life science field -- genome editing, deep sequencing and machine learning.

## Funding rounds

- Seed, May 3, 2022, $16M — Novo Holdings, Pureos Bioventures

## Investors

- Novo Holdings — Seed
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Seed